FDA Determines Regulatory Review Period for ANZUPGO Patent Extension Application

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for ANZUPGO, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to the submission of an application to the U.S. Patent and Trademark Office (USPTO) for patent extension.